Yi Xia, MD

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, China (People's Republic)

Yi Xia, M.D. & Ph.D.
Attending physician
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China.
Specialized in conducting clinical and molecular research focused specifically on lymphoid malignancies.
Currently focusing on a collaborative project focusing on retrospective analysis of immunogenetic profiles in Chinese patients with chronic lymphocytic leukemia (CLL)。

Poster(s):

• 1102 - Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance

• 1103 - Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients

• 1128 - Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia

• 1145 - The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL

• 1209 - Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort

• 1228 - Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)